Moexipril (BioDeep_00001868398)
Main id: BioDeep_00000002767
代谢物信息卡片
Moexipril
化学式: C27H34N2O7 (498.2366)
中文名称: 莫西普利
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC(=C(C=C3CC2C(=O)O)OC)OC
InChI: InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
描述信息
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
同义名列表
数据库引用编号
11 个数据库交叉引用编号
- ChEBI: CHEBI:6960
- KEGG: C07704
- KEGGdrug: D08225
- PubChem: 91270
- DrugBank: DB00691
- ChEMBL: CHEMBL1165
- CAS: 109715-88-0
- CAS: 103775-10-6
- PubChem: 9906
- NIKKAJI: J557.758F
- KNApSAcK: 6960
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- A Rodrigues, A Gaffard, J Moreau, K Monceau, O Delhomme, M Millet. Analytical development for the assessment of pesticide contaminations in blood and plasma of wild birds: The case of grey partridges (Perdix perdix).
Journal of chromatography. A.
2023 Jan; 1687(?):463681. doi:
10.1016/j.chroma.2022.463681. [PMID: 36502641] - R H Mohamed, H R Abdel-Aziz, D M Abd El Motteleb, T A Abd El-Aziz. Effect of RAS inhibition on TGF-β, renal function and structure in experimentally induced diabetic hypertensive nephropathy rats.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2013 Apr; 67(3):209-14. doi:
10.1016/j.biopha.2009.08.002. [PMID: 20089379] - Vijaya Kumari Karra, Ramesh Mullangi, Nageswara Rao Pilli, Jaswanth Kumar Inamadugu, Vasu Babu Ravi, J V L N Seshagiri Rao. A rapid and sensitive liquid chromatography-tandem mass spectrometric assay for moexipril, an angiotensin-converting enzyme inhibitor in human plasma.
Biomedical chromatography : BMC.
2012 Dec; 26(12):1552-8. doi:
10.1002/bmc.2731. [PMID: 22419504] - Phunchai Charatcharoenwitthaya, Jayant A Talwalkar, Paul Angulo, Andrea A Gossard, Jill C Keach, Janice L Petz, Roberta A Jorgensen, Keith D Lindor. Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
Digestive diseases and sciences.
2010 Feb; 55(2):476-83. doi:
10.1007/s10620-009-0744-1. [PMID: 19255851] - Ilka Knütter, Claudia Wollesky, Gabor Kottra, Martin G Hahn, Wiebke Fischer, Katja Zebisch, Reinhard H H Neubert, Hannelore Daniel, Matthias Brandsch. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.
The Journal of pharmacology and experimental therapeutics.
2008 Nov; 327(2):432-41. doi:
10.1124/jpet.108.143339. [PMID: 18713951] - J Kóti, V Háda, G Petroianu, M Y Hasan, K Tekes, Z Szücs, H Kalász. Monitoring the metabolism of moexipril to moexiprilat using high-performance liquid chromatography-electrospray ionization mass spectrometry.
Journal of chromatographic science.
2006 Apr; 44(4):214-8. doi:
10.1093/chromsci/44.4.214. [PMID: 16620521] - M V Leonova, M A Demidova, A V Tarasov, Iu B Belousov. [Comparative efficacy and safety of contemporary Angiotensin converting enzyme inhibitors moexipril and spirapril in women with postmenopausal metabolic syndrome].
Kardiologiia.
2006; 46(1):43-9. doi:
. [PMID: 16474309] - J Spinar, J Vítovec. MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial.
International journal of cardiology.
2005 Apr; 100(2):199-206. doi:
10.1016/j.ijcard.2004.05.077. [PMID: 15823625] - Iu B Belousov, M G Glezer, E B Tkhostova, M A Demidova. [Moexipril influence on quality of life in postmenopausal women with arterial hypertension].
Terapevticheskii arkhiv.
2005; 77(10):75-8. doi:
. [PMID: 16320692] - Steven G Chrysant, George S Chrysant. Pharmacological and clinical profile of moexipril: a concise review.
Journal of clinical pharmacology.
2004 Aug; 44(8):827-36. doi:
10.1177/0091270004267194. [PMID: 15286086] - Amos Pines, Enrique Z Fisman. ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2003; 3(5):351-60. doi:
10.2165/00129784-200303050-00006. [PMID: 14728069] - A Torsello, V Locatelli, S G Cella, A M Sanguini, F Berti. Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation.
Journal of endocrinological investigation.
2003 Jan; 26(1):79-83. doi:
10.1007/bf03345127. [PMID: 12602539] - Enrique Z Fisman, Alexander Tenenbaum, Amos Pines. Systemic hypertension in postmenopausal women: a clinical approach.
Current hypertension reports.
2002 Dec; 4(6):464-70. doi:
10.1007/s11906-002-0027-0. [PMID: 12419176] - Theo Pelzer, Tertia de Jager, Jenny Muck, Michael Stimpel, Ludwig Neyses. Oestrogen action on the myocardium in vivo: specific and permissive for angiotensin-converting enzyme inhibition.
Journal of hypertension.
2002 May; 20(5):1001-6. doi:
10.1097/00004872-200205000-00036. [PMID: 12011662] - Jessica C Song, C Michael White. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
Clinical pharmacokinetics.
2002; 41(3):207-24. doi:
10.2165/00003088-200241030-00005. [PMID: 11929321] - W Cawello, H Boekens, J Waitzinger, U Miller. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
International journal of clinical pharmacology and therapeutics.
2002 Jan; 40(1):9-17. doi:
10.5414/cpp40009. [PMID: 11837383] - J Blacher, J Raison, G Amah, A L Schiemann, M Stimpel, M E Safar. Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril.
Cardiovascular drugs and therapy.
1998 Sep; 12(4):409-14. doi:
10.1023/a:1007733103730. [PMID: 9825188] - R N Brogden, L R Wiseman. Moexipril. A review of its use in the management of essential hypertension.
Drugs.
1998 Jun; 55(6):845-60. doi:
10.2165/00003495-199855060-00018. [PMID: 9617599] - M Stimpel, B Koch, S Oparil. Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide).
Cardiology.
1998 May; 89(4):271-6. doi:
10.1159/000006799. [PMID: 9643274] - C M White. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.
Pharmacotherapy.
1998 May; 18(3):588-99. doi:
. [PMID: 9620109] - R Gietl, H Friehe, P Ney. Preclinical safety studies of the combination moexipril hydrochloride/hydrochlorothiazide.
Arzneimittel-Forschung.
1998 Apr; 48(4):365-70. doi:
. [PMID: 9608878] - H Friehe, P Ney. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
Arzneimittel-Forschung.
1997 Feb; 47(2):132-44. doi:
. [PMID: 9079232] - S G Chrysant, M Stimpel. A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide.
Journal of clinical pharmacology.
1996 Aug; 36(8):701-6. doi:
10.1002/j.1552-4604.1996.tb04238.x. [PMID: 8877673] - V Hutt, K Michaelis, R Verbesselt, P J De Schepper, P Salomon, R Bonn, W Cawello, J C Angehrn. Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide.
European journal of clinical pharmacology.
1996; 51(3-4):339-44. doi:
10.1007/s002280050209. [PMID: 9010710] - B Persson, M Stimpel. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients.
European journal of clinical pharmacology.
1996; 50(4):259-64. doi:
10.1007/s002280050104. [PMID: 8803515] - O Edling, G Bao, M Feelisch, T Unger, P Gohlke. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
The Journal of pharmacology and experimental therapeutics.
1995 Nov; 275(2):854-63. doi:
. [PMID: 7473177] - G R De Meyer, H Bult, M M Kockx, A G Herman. Effect of angiotensin-converting enzyme inhibition on intimal thickening in rabbit collared carotid artery.
Journal of cardiovascular pharmacology.
1995 Oct; 26(4):614-20. doi:
10.1097/00005344-199510000-00017. [PMID: 8569224] - W Hammes, B Hammes, U Büchsler, F Paar, H Bökens. Simultaneous determination of moexipril and moexiprilat, its active metabolite, in human plasma by gas chromatography-negative-ion chemical ionization mass spectrometry.
Journal of chromatography. B, Biomedical applications.
1995 Aug; 670(1):81-9. doi:
10.1016/0378-4347(95)00135-6. [PMID: 7493088] - S G Chrysant, A A Fox, M Stimpel. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients.
American journal of hypertension.
1995 Apr; 8(4 Pt 1):418-21. doi:
10.1016/0895-7061(94)00025-7. [PMID: 7619356] - N Perico, S C Amuchastegui, V Colosio, G Sonzogni, T Bertani, G Remuzzi. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started.
Journal of the American Society of Nephrology : JASN.
1994 Oct; 5(4):1139-46. doi:
10.1681/asn.v541139. [PMID: 7849255] - A Van Hecken, R Verbesselt, M Depré, T B Tjandramaga, J Angehrn, W Cawello, P J De Schepper. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.
European journal of clinical pharmacology.
1993; 45(3):291-3. doi:
10.1007/bf00315400. [PMID: 8276058] - G M Grass, W T Morehead. Evidence for site-specific absorption of a novel ACE inhibitor.
Pharmaceutical research.
1989 Sep; 6(9):759-65. doi:
10.1023/a:1015919413103. [PMID: 2554270] - D L McClelland, R P Rosenkranz. Synergistic renal effects of RS-10085, an ace inhibitor, and fenoldopam, a DA1 agonist, in the rat.
Proceedings of the Western Pharmacology Society.
1988; 31(?):87-90. doi:
. [PMID: 2905468]
